Saudi Medical Devices Authority Approves Proton Therapy System
By MedImaging International staff writers Posted on 24 Jan 2016 |
The Saudi Arabian Food and Drug Administration (Saudi FDA) has authorized the first proton therapy system, intended for cancer treatment, for marketing in the country.
Similar systems are installed at the Scripps Proton Therapy Center (San Diego, CA, USA), the Rinecker Proton Therapy Center (Munich, Germany, and the Paul Scherrer Institute (Villingen, Switzerland), and installation is planned at another 13 sites worldwide. The success of proton therapy treatments is rapidly enabling a transition of the therapy out of research facilities into regional treatment centers worldwide, together with increasingly sophisticated imaging delivery, and scanning techniques.
The ProBeam proton therapy system was developed by Varian Medical Systems (Palo Alto, CA, USA), a leading manufacturer of cancer treatment hardware and software. Proton therapy enables certain cancers to be treated earlier, more precisely, and with potentially less side effects than other methods by reducing the risk of damaging healthy tissues. Proton therapy is suitable for many types of cancers such as tumors in the spinal cord, brain, lung, breast, prostate, lymphoma, head and neck, bone and soft tissue, gynecologic carcinoma, cancers of the eye, and other cancers located close to radiosensitive tissues. Proton therapy is especially useful for use with pediatric patients, and can reduce the risk of young patients developing new, radiation-induced cancers later in life.
Moataz Karmalawy, GM, Varian Medical Systems, Particle Therapy business, said, "We are pleased to have the opportunity to make life-saving proton therapy treatments available to cancer patients in this region."
Related Links:
Varian
Saudi Arabian FDA
Similar systems are installed at the Scripps Proton Therapy Center (San Diego, CA, USA), the Rinecker Proton Therapy Center (Munich, Germany, and the Paul Scherrer Institute (Villingen, Switzerland), and installation is planned at another 13 sites worldwide. The success of proton therapy treatments is rapidly enabling a transition of the therapy out of research facilities into regional treatment centers worldwide, together with increasingly sophisticated imaging delivery, and scanning techniques.
The ProBeam proton therapy system was developed by Varian Medical Systems (Palo Alto, CA, USA), a leading manufacturer of cancer treatment hardware and software. Proton therapy enables certain cancers to be treated earlier, more precisely, and with potentially less side effects than other methods by reducing the risk of damaging healthy tissues. Proton therapy is suitable for many types of cancers such as tumors in the spinal cord, brain, lung, breast, prostate, lymphoma, head and neck, bone and soft tissue, gynecologic carcinoma, cancers of the eye, and other cancers located close to radiosensitive tissues. Proton therapy is especially useful for use with pediatric patients, and can reduce the risk of young patients developing new, radiation-induced cancers later in life.
Moataz Karmalawy, GM, Varian Medical Systems, Particle Therapy business, said, "We are pleased to have the opportunity to make life-saving proton therapy treatments available to cancer patients in this region."
Related Links:
Varian
Saudi Arabian FDA
Latest Nuclear Medicine News
- New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment